ArticleScience advances2018
Mass spectrometry imaging of the in situ drug release from nanocarriers.
Article in Science advances, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 91 citations in OpenAlex.
- Interface-engineered plasmonic covalent organic framework nanofilms on TiOScience advances · 2026Article
- Lipid nanoparticles and extracellular vesicles: emerging cell free therapeutic platforms for hepatobiliary cancers.Frontiers in cell and developmental biology · 2026Review
- Next Generation DNA Damage Response Inhibitors: Harnessing Nanocarriers and Tumor Microenvironment for Precision Cancer Therapy.Oncology research · 2026Review
- Review of methods for the determination of cellular cholesterol content: principles, advantages, limitations, applications, and perspectives.Analytical sciences : the international journal of the Japan Society for Analytical Chemistry · 2025Review
- Innovative nanocarriers: Synthetic and biomimetic strategies for enhanced drug delivery.Materials today. Bio · 2025Review
- Two-dimensional nanomaterials for bone disease therapy: multifunctional platforms for regeneration, anti-infection and tumor ablation.Journal of nanobiotechnology · 2025Review
- Determination of insulin with ultra-performance liquid chromatography tandem mass spectrometry enhanced by Mg-based micromotors.Mikrochimica acta · 2025Article
- Mass spectrometry imaging for unearthing and validating quality markers in traditional Chinese medicines.Chinese herbal medicines · 2025Review
- Environmental and Health Impacts of Graphene and Other Two-Dimensional Materials: A Graphene Flagship Perspective.ACS nano · 2024Review
- Spatial pharmacology using mass spectrometry imaging.Trends in pharmacological sciences · 2024Review
- Microlensed fiber allows subcellular imaging by laser-based mass spectrometry.Nature protocols · 2023Review
- Molecular-level degradation pathways of black phosphorus revealed by mass spectrometry fingerprinting.Chemical science · 2023Article
- Mass spectrometry imaging: new eyes on natural products for drug research and development.Acta pharmacologica Sinica · 2022Review
- Multiplexed Analysis of the Cellular Uptake of Polymeric Nanocarriers.Analytical chemistry · 2022Article
- Recent advances in on-site mass spectrometry analysis for clinical applications.Trends in analytical chemistry : TRAC · 2022Review
- Self-supervised clustering of mass spectrometry imaging data using contrastive learning.Chemical science · 2021Article
- Mass spectrometry-based chemical mapping and profiling toward molecular understanding of diseases in precision medicine.Chemical science · 2021Review
- Design and optimisation of dendrimer-conjugated Bcl-2/xCommunications biology · 2021Article
- Revealing the Distribution of Aggregation-Induced Emission Nanoparticles via Dual-Modality Imaging with Fluorescence and Mass Spectrometry.Research (Washington, D.C.) · 2021Article
- Spatial heterogeneity of nanomedicine investigated by multiscale imaging of the drug, the nanoparticle and the tumour environment.Theranostics · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It is crucial but of a great challenge to study in vivo and in situ drug release of nanocarriers when developing a nanomaterial-based drug delivery platform. We developed a new label-free laser desorption/ionization mass spectrometry (MS) imaging strategy that enabled visualization and quantification of the in situ drug release in tissues by monitoring intrinsic MS signal intensity ratio of loaded drug over the nanocarriers. The proof of concept was demonstrated by investigating the doxorubicin (DOX)/polyethylene glycol-MoS
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.